23:24 , May 15, 2019 |  BC Extra  |  Company News

Management tracks: Biogen’s McKenzie departing for CSL; plus Rubius, SanBio, Avita and more

Paul McKenzie is leaving Biogen Inc. (NASDAQ:BIIB) as EVP, pharmaceutical operations & technology to become COO of CSL Ltd. (ASX:CSL). A veteran of Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co....
15:43 , May 4, 2018 |  BC Week In Review  |  Clinical News

Avita reports data from pivotal trial of ReCell for second-degree burns

Avita Medical Ltd. (ASX:AVH; OTCQX:AVMXY) reported data from a pivotal trial evaluating ReCell to treat deep partial-thickness (second-degree) burns. ReCell is a point-of-care autologous cell harvesting device that creates a regenerative epithelial suspension (RES) to...
15:09 , May 4, 2018 |  BC Week In Review  |  Clinical News

Avita's ReCell meets in pivotal trial for third-degree burns

Avita Medical Ltd. (ASX:AVH; OTCQX:AVMXY) said ReCell met the co-primary endpoints in a pivotal trial to treat deep full-thickness (third-degree) burns. ReCell is a point-of-care autologous cell harvesting device that creates a regenerative epithelial suspension...
00:02 , Dec 7, 2017 |  BC Extra  |  Company News

Management Tracks: Sunesis, Vital

Cancer company Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) said President and CEO Daniel Swisher will step down, effective Dec. 31. He will join Jazz Pharmaceuticals plc (NASDAQ:JAZZ) as president and COO. Director Dayton Misfeldt will serve as...
22:43 , Sep 8, 2017 |  BC Extra  |  Company News

Management tracks: Karolinska, Conatus, Theranexus

Life sciences investment company Karolinska Development AB (SSE:KDEV) named Fredrik Järrsten CFO effective "towards the end" of the year. He is CFO and business development director at Bactiguard Holding AB (SSE:BACTI-B). Liver disease play Conatus...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Company News

Avita, U.S. Department of Health and Human Services dermatology, gene/cell therapy news

HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded Avita an $8 million extension to support U.S. approval and launch of Avita’s ReCell device. Last September, BARDA awarded Avita a five-year contract worth up to...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Financial News

Avita completes rights offering

Avita Medical Ltd. (ASX:AVH; OTCQX:AVMXY), Perth, Australia   Business: Gene/Cell therapy, Dermatology   Date completed: 2016-07-04   Type: Rights offering   Raised: A$9 million ($6.8 million)   Shares: 100.2 million   Price: A$0.09   Shares...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Clinical News

ReGenerCell: Phase IV data

An open-label, European Phase IV trial in 52 patients with chronic venous leg ulcers showed that ReGenerCell plus standard of care (SOC) non-significantly improved the rate of complete wound closure vs. SOC alone (26.9% vs....
07:00 , Mar 14, 2016 |  BC Week In Review  |  Company News

Avita sales and marketing update

Avita launched ReGenerCell and ReNovaCell in Europe. Both autologous cell harvesting devices have CE Mark approval. ReGenerCell is approved to treat chronic wounds, such as venous leg ulcers and diabetic foot ulcers. ReNovaCell is approved...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Company News

Avita, Medical Developments International deal

Avita will sell its respiratory business, including the Breath-A-Tech and Funhaler asthma spacers, to Medical Developments. Breath-A-Tech and Funhaler are marketed in Australia. The deal is expected to close by early February. Avita will receive...